Download PDF
CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2019; 28(03): 216-217
DOI: 10.1055/s-0038-1667057
Article of Reflection | Artículo de Reflexión
Sociedad Colombiana de Urología. Publicado por Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Una sola tableta de Abiraterona con comida en vez de 4 tabletas en ayuno para pacientes con cáncer de próstata metastásico resistente a la castración: perspectivas fármaco-económicas en un país en desarrollo

One Pill of Abiraterone with Food Instead of Four Pills in Fasting State for Metastatic Castration Resistant Prostate Cancer Patients: Pharmaco-economic Perspectives in a Developing Country
Pablo S. Sierra
1   Departamento de Urología oncológica, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, São Paulo, Brasil
2   Departamento de Urología, Fundación Valle del lili- Universidad ICESI, Cali, Valle del Cauca, Colombia
› Author Affiliations
Further Information

Publication History

09 April 2018

18 June 2018

Publication Date:
09 July 2018 (online)

Also available at
   Permissions and Reprints

Resumen

Recientemente se publicó en el Journal of Clinical Oncology un estudio prospectivo aleatorizado fase II, que comparó dosis bajas de Abiraterona (250mg) administrada con comida vs la dosis estándar de dicho medicamento (1000mg), en pacientes con cáncer de próstata metastásico resistente a la castración (mCRPC)1 y concluyó que la dosis baja no es inferior a la dosis estándar en cuanto a la respuesta de PSA y a la supervivencia libre de progresión (PFS).

Abstract

A prospective randomized phase II study comparing low dose Abiraterone (250 mg) administered with food versus the standard dose (1000 mg) in metastatic castration resistant prostate cancer, was recently published in The Journal of Clinical Oncology. It concluded that the low dose was non-inferior compared to the standard dose for the endpoints prostate specific antigen (PSA) response and progression free survival (PFS).

Palabras Clave

Abiraterona - Neoplasia Prostática - Cáncer de próstata - Cáncer de próstata metastásico resistente a la castración - Supervivencia especifica

Keywords

abiraterone - prostatic neoplasm - prostate cancer - metastatic castration resistant prostate cancer - pharmacology - cancer specific survival
 

  • Referencias

  • 1 Szmulewitz RZ, Peer CJ, Ibraheem A. , et al. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 2018; 36 (14) 1389-1395
    CrossrefPubMedGoogle Scholar
  • 2 Ryan CJ, Smith MR, Fong L. , et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28 (09) 1481-1488
    CrossrefPubMedGoogle Scholar
  • 3 Stuyckens K, Saad F, Xu XS. , et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet 2014; 53 (12) 1149-1160
    CrossrefPubMedGoogle Scholar
  • 4 Fizazi K, Tran N, Fein L. , et al; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377 (04) 352-360
    CrossrefPubMedGoogle Scholar
  • 5 James ND, de Bono JS, Spears MR. , et al; STAMPEDE Investigators. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377 (04) 338-351
    CrossrefPubMedGoogle Scholar
  • 6 Malangone-Monaco E, Foley K, Varker H, Wilson KL, McKenzie S, Ellis L. Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: Results of an oncology EMR analysis. Clin Ther 2016; 38 (08) 1817-1824
    CrossrefPubMedGoogle Scholar
  • 7 Rincón LM, Gamboa OA, Gamboa CA, Romano G, González CA. Análisis de impacto presupuestal de hormonoterapia para el tratamiento de cáncer de próstata en Colombia. Bogotá D.C: Instituto de Evaluación Tecnológica en Salud -IETS y Ministerio de Salud y Protección Social; 2017
    Google Scholar
  • 8 Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, Bogotá: Instituto Nacional de Cancerología; 2011
  • 9 Kolesar JM, Liu GX. Low-Fat Abiraterone Food Effect Is of Little Consequence. J Clin Oncol 2018; 36 (14) 1385-1386
    CrossrefPubMedGoogle Scholar